+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis



Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis



Alimentary Pharmacology and Therapeutics 43(8): 910-923



Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation. To establish outcomes following anti-TNF withdrawal for sustained remission using new data from a large UK cohort, and assimilation of all available literature for systematic review and meta-analysis. A retrospective observational study was performed on 166 patients with IBD (146 with Crohn's disease (CD) and 20 with ulcerative colitis [UC) and IBD unclassified (IBDU)] withdrawn from anti-TNF for sustained remission. Meta-analysis was undertaken of all published studies incorporating 11 further cohorts totalling 746 patients (624 CD, 122 UC). Relapse rates in the UK cohort were 36% by 1 year and 56% by 2 years for CD, and 42% by 1 year and 47% by 2 years for UC/IBDU. Increased relapse risk in CD was associated with age at diagnosis [hazard ratio (HR) 2.78 for age <22 years], white cell count (HR 3.22 for >5.25 × 109 /L) and faecal calprotectin (HR 2.95 for >50 μg/g) at drug withdrawal. Neither continued immunomodulators nor endoscopic remission were predictors. In the meta-analysis, estimated 1-year relapse rates were 39% and 35% for CD and UC/IBDU respectively. Retreatment with anti-TNF was successful in 88% for CD and 76% UC/IBDU. Assimilation of all available data reveals remarkable homogeneity. Approximately one-third of patients with IBD flare within 12 months of withdrawal of anti-TNF therapy for sustained remission.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058727354

Download citation: RISBibTeXText

PMID: 26892328

DOI: 10.1111/apt.13547


Related references

OC-009 Withdrawal of anti-tnf following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis. Gut 64(Suppl 1): A5.1-A5, 2015

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 39(5): 447-458, 2014

Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. European Journal of Clinical Pharmacology 71(8): 911-919, 2015

Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Alimentary Pharmacology and Therapeutics 42(4): 391-405, 2015

Histologic Disease Activity as a Predictor for Clinical Relapse Among Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Gastroenterology 150(4): S211-S212, 2016

Sa1228 Predictors of Relapse Following Withdrawal of Anti-Tnf Agents in Patients With Crohn's Disease in Remission - A Systematic Review and Meta-Analysis. Gastroenterology 148(4): S-264, 2015

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease. Zeitschrift für Gastroenterologie 55(1): 85, 2017

Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. Inflammatory Bowel Diseases 20(7): 1217-1226, 2014

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Alimentary Pharmacology and Therapeutics 41(7): 613-623, 2015

Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies. European Journal of Nutrition 2019:, 2019

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Alimentary Pharmacology and Therapeutics 38(10): 1255-1266, 2013

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Bmj 327(7407): 128, 2003

Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases 20(10): 1862-1869, 2014

Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's and Colitis 8(12): 1569-1581, 2014

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases 21(11): 2696-2707, 2015